Farxiga and Simvastatin Interaction: Can You Take Dapagliflozin with a Statin?

Direct answer

Dapagliflozin (Farxiga), an SGLT2 inhibitor indicated for type 2 diabetes, heart failure, and chronic kidney disease, undergoes metabolism primarily via UGT1A9-mediated glucuronidation with negligible CYP enzyme involvement. Simvastatin (Zocor, available in generic form) requires CYP3A4-mediated metabolism for both activation and elimination. Given the absence of shared metabolic pathways between these agents, no pharmacokinetic mechanism exists through which dapagliflozin would alter simvastatin levels or simvastatin would alter dapagliflozin levels. This assessment is based on pharmacologic data from drug labeling and theoretical mechanisms rather than a prospective clinical trial specifically evaluating dapagliflozin and simvastatin together; consequently, formal clinical interaction evidence for this combination remains absent.

Why these two drugs end up prescribed together

Many adults treated with dapagliflozin for type 2 diabetes, heart failure, or chronic kidney disease also have cardiovascular risk factors that call for statin therapy. Diabetes treatment guidelines have long recommended moderate- to high-intensity statins for most adults with type 2 diabetes within a defined age range, and separately recommend SGLT2 inhibitors such as dapagliflozin for patients with established cardiovascular disease, heart failure, or chronic kidney disease. A patient who meets both sets of criteria is commonly prescribed both drugs. The current version of these recommendations should be checked against the American Diabetes Association's active Standards of Care, since specific age cutoffs and risk thresholds are updated periodically.

Because simvastatin is well known for CYP3A4-related interactions, with drugs such as certain azole antifungals, macrolide antibiotics, HIV protease inhibitors, and some calcium-channel blockers capable of raising simvastatin exposure and rhabdomyolysis risk, it is reasonable for a patient or prescriber to ask whether adding dapagliflozin introduces a similar concern. The mechanistic answer is no, for the reasons below.

Do the metabolism pathways actually cross?

Dapagliflozin is cleared primarily through UGT1A9-mediated glucuronidation, producing an inactive glucuronide metabolite. The FDA-approved prescribing information for Farxiga describes CYP-mediated metabolism as a minor clearance route, and in vitro data cited in the label indicate dapagliflozin does not meaningfully inhibit or induce the major CYP enzymes, including CYP3A4 as described in the FDA-approved Farxiga prescribing information.

Simvastatin is a lactone prodrug that requires CYP3A4-dependent oxidation to become its active beta-hydroxy acid form. The simvastatin label warns against combining it with strong CYP3A4 inhibitors such as itraconazole, ketoconazole, erythromycin, and HIV protease inhibitors, and sets lower dose ceilings when combined with moderate CYP3A4-interacting drugs such as amiodarone or verapamil (simvastatin label, FDA, 2012 revision). That label revision is more than a decade old; a current label check is reasonable before relying on exact dose caps.

Because dapagliflozin is not a CYP3A4 inhibitor or inducer, it has no described mechanism for raising or lowering simvastatin blood levels. The reverse direction also has no identified mechanism: simvastatin is not known to inhibit UGT1A9 at clinically relevant exposures, so it should not impair dapagliflozin's glucuronidation. No P-glycoprotein interaction of clinical significance between the two drugs has been described in the available labeling.

What the large outcome trials suggest, and what they do not prove

Dapagliflozin's major cardiovascular and renal outcome trials, including the type 2 diabetes cardiovascular outcomes trial, the heart failure with reduced ejection fraction trial, and the chronic kidney disease trial, enrolled large numbers of patients who were also taking statins at baseline, since statin use is standard care in these populations. None of these trials excluded statin users, and none of their published safety reporting describes an excess of muscle-related adverse events or rhabdomyolysis in the dapagliflozin arm compared with placebo.

This is reassuring background evidence, but it has a real limit: these trials were designed to test dapagliflozin's cardiovascular and renal effects, not to isolate a dapagliflozin-simvastatin interaction. Background statin use was common but not restricted to simvastatin, and the trials were not powered or designed to detect a rare statin-specific interaction signal. Exact event rates, hazard ratios, and confidence intervals from these trials should be pulled from the original trial publications before being cited precisely, since specific numbers were not independently re-verified for this article.

Evidence-status map for this interaction

Simvastatin's real interaction risks are elsewhere

Dapagliflozin is not the interaction to worry about. Simvastatin's own label restricts dosing when combined with amiodarone, amlodipine, or ranolazine, and sets a lower ceiling when combined with verapamil or diltiazem. It is contraindicated with strong CYP3A4 inhibitors, gemfibrozil, cyclosporine, and danazol (simvastatin label, FDA). Anyone adding a new medication to an existing simvastatin regimen should have that medication screened for CYP3A4 activity, independent of whether dapagliflozin is also on the list.

For patients on complex regimens with multiple CYP3A4-active drugs, a prescriber may consider a statin with less CYP3A4 dependence, such as rosuvastatin or pitavastatin. That is a general statin-selection consideration and is not driven by dapagliflozin use.

Pharmacodynamic considerations, not a drug interaction

Dapagliflozin and simvastatin can each affect the kidney and metabolism through unrelated mechanisms, which is worth distinguishing from a true drug interaction. Dapagliflozin commonly causes a small, early reversible dip in estimated glomerular filtration rate that reflects reduced glomerular hyperfiltration rather than kidney injury, and this effect is associated with longer-term renal protection in the chronic kidney disease trial population. Statins have been linked in some analyses to mild changes in urinary protein, generally considered a tubular effect rather than glomerular damage; the strength and consistency of this statin-proteinuria association across the general statin-using population were not independently verified for this article and should be checked in the primary nephrology literature before being stated as settled.

On glucose, dapagliflozin lowers blood sugar through renal glucose excretion, while statins, especially at higher intensity, are associated with a small increase in incident diabetes risk across pooled trial data. These are two independent, well-documented drug effects moving in different metabolic directions. They do not interact with each other pharmacologically; each should be monitored on its own terms rather than assumed to offset or compound the other.

What to monitor when taking both drugs

No monitoring specific to the dapagliflozin-simvastatin combination is described in the available guidance. Standard monitoring for each drug individually applies:

For simvastatin, a fasting lipid panel is typically checked several weeks after starting or adjusting the dose, then periodically. Patients should report unexplained muscle pain, tenderness, or weakness; a creatine kinase level is appropriate if symptoms develop, not as a routine screening test.

For dapagliflozin, kidney function and potassium are typically checked shortly after starting treatment and periodically thereafter. Patients should be counseled about genital mycotic infection symptoms and, in rare cases, euglycemic diabetic ketoacidosis, particularly around surgery, illness, or prolonged fasting.

If a patient develops muscle symptoms while on both drugs, dapagliflozin is not a plausible contributor based on current mechanistic evidence. The more useful step is reviewing the rest of the medication list for known simvastatin interaction culprits: new antibiotics, antifungals, calcium-channel blockers, or heavy grapefruit intake. Reversible causes such as hypothyroidism or excess physical exertion are also worth ruling out before attributing symptoms to the statin itself, consistent with general dyslipidemia management guidance.

When urgent care is appropriate

Severe, unexplained muscle pain with weakness, dark or tea-colored urine, or markedly reduced urination can indicate rhabdomyolysis and warrants prompt medical evaluation regardless of which drugs are involved. Nausea, vomiting, abdominal pain, and unusual fatigue in a person on dapagliflozin, particularly around a surgery, illness, or very low-carbohydrate intake, can be early signs of diabetic ketoacidosis even with a normal blood glucose, and also warrants urgent evaluation. Neither of these presentations is expected to be caused by a dapagliflozin-simvastatin interaction itself, but both are reasons to seek care rather than waiting for a routine visit.

Does this hold for other SGLT2 inhibitors and other statins?

The other FDA-approved SGLT2 inhibitors follow a similar metabolic pattern. Empagliflozin (Jardiance) is cleared mainly through UGT-mediated glucuronidation and its label does not describe clinically relevant CYP3A4 inhibition or induction as described in the FDA-approved Jardiance prescribing information. Canagliflozin (Invokana) is similarly cleared through UGT1A9-related pathways without a described CYP3A4 effect as described in the FDA-approved Invokana prescribing information. No SGLT2 inhibitor currently approved in the United States lists a statin interaction on its label. That said, "no other SGLT2 inhibitor has this issue" is a pattern observed across labels rather than a claim independently tested for every statin-SGLT2 inhibitor pairing, and atorvastatin, lovastatin, and other CYP3A4-dependent statins should be assumed to follow the same reasoning as simvastatin rather than assumed identical without checking the relevant labels.

What is established, what is plausible, and what is not established

Established: dapagliflozin does not meaningfully affect CYP3A4, and simvastatin's known interaction risks come from other CYP3A4-active drugs, not from SGLT2 inhibitors. This is grounded directly in FDA labeling for both drugs.

Plausible but not directly proven by a dedicated study: the absence of any clinically meaningful interaction between dapagliflozin and simvastatin specifically. This is a reasonable inference from non-overlapping metabolic pathways and from the absence of a muscle-toxicity signal in large trials with substantial background statin use, but a dedicated pharmacokinetic interaction study of this exact pair was not identified in the source material reviewed for this article.

Not established: any claim that combining the two drugs changes dosing requirements, requires extra monitoring beyond each drug's individual standard of care, or produces a pharmacodynamic effect on the kidney or glucose metabolism beyond each drug's independent, well-described action.